Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2015 | How far are we from a cure for CLL?

Thomas Kipps • 4 Dec 2015
ASH 2015
Chronic Lymphocytic Leukemia

Thomas Kipps, MD from the University of California, San Diego, CA, discussed the current treatment landscape in chronic lymphocytic leukemia (CLL), considering the novel therapies being presented at the American Society of Hematology (ASH) 2015 Annual Meeting.

More from Thomas Kipps

Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib
3:37
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib
Thomas Kipps • 5 Dec 2025
Overcoming challenges with targeted therapies for CLL: high-risk mutations and BTKi resistance
3:09
Overcoming challenges with targeted therapies for CLL: high-risk mutations and BTKi resistance
Thomas Kipps • 6 Sep 2024
Genetic testing to risk stratify patients with CLL and aid in treatment decisions
2:11
Genetic testing to risk stratify patients with CLL and aid in treatment decisions
Thomas Kipps • 6 Sep 2024
A long-term analysis of lenalidomide and rituximab for the treatment of CLL
1:28
A long-term analysis of lenalidomide and rituximab for the treatment of CLL
Thomas Kipps • 11 Dec 2023

Related Videos

Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Thomas Kipps • 6 Dec 2025
Translating academic-center data to community settings to improve the adoption of bispecifics
1:54
Translating academic-center data to community settings to improve the adoption of bispecifics
Thomas Kipps • 8 Dec 2025
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
1:30
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
Thomas Kipps • 7 Dec 2025
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
0:53
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
Thomas Kipps • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals